Moderna, Intellia Therapeutics, and Ginkgo Bioworks: 3 Stocks with Explosive Growth Potential
-
Moderna's stock has declined but has significant growth potential from its COVID-19 vaccine and robust pipeline of 15 upcoming product launches.
-
Intellia Therapeutics uses innovative CRISPR gene editing technology and aims to complete pivotal trials and apply for regulatory approval of two therapies by 2026.
-
Ginkgo Bioworks partners with biopharma companies to improve drug development and manufacturing, with revenue and programs growing rapidly.
-
Intellia and Ginkgo stocks could deliver explosive long-term growth.
-
The article recommends Moderna, Intellia Therapeutics, and Ginkgo Bioworks as stocks that could soar in the current bull market.